learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 13 resultslearn sh-Polypeptide-7
learn Overview
learn Vascular Endothelial Growth Factor
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Research
5 / 1000+ results
research Compilation of a Comprehensive Gene Panel for Systematic Assessment of Genes That Govern an Individual’s Drug Responses
Researchers found that most genes affecting drug responses are not fully covered by commercial SNP chips, suggesting the need for more comprehensive tools to optimize drug selection based on genetics.
research Androgenetic Alopecia And Hair Growth Promotion: Present And Future
Current research explores hair growth drugs, while future research aims for personalized treatments.
research Chitosan Nanoparticles for Topical Drug Delivery in Chemotherapy-Induced Alopecia: A Comparative Study of Five Repurposed Pharmacological Agents
Phenobarbital-loaded chitosan nanoparticles are promising for preventing hair loss from chemotherapy.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Frozen Glove Therapy for Docetaxel-Induced Hand Problems May Not Fit All
Wearing a frozen glove during chemotherapy can reduce nail and skin problems but may not be comfortable for everyone.
Community Join
5 / 1000+ resultscommunity Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
community What happened to that drug that kills dht receptors in your scalp
A new therapy aimed at destroying DHT receptors in the scalp is still in early trials and may take at least 5 years to become available. A sugar-like solution similar to Minoxidil is also in early testing stages and not yet commercialized.
community A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
community Is there any new drug that looks promising ?
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
community About GT20029's Efficacy and Strength
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.